Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 30th, there was short interest...
MarketBeat·13d ago
More News
Prelude Therapeutics (NASDAQ:PRLD) Trading Down 0.9% - Should You Sell?
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Down 0.9% - What's Next...
MarketBeat·20d ago
Why Did PRLD Stock Surge 13% Today?
Prelude Therapeutics said on Tuesday that the FDA gave clearances to proceed with early-stage trials for its experimental drug PRT12396.
Stocktwits·26d ago
Prelude Therapeutics (NASDAQ:PRLD) Rating Lowered to Hold at Wall Street Zen
Wall Street Zen cut Prelude Therapeutics from a "buy" rating to a "hold" rating in a research note on Sunday...
MarketBeat·1mo ago
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 28.5% in December
Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest...
MarketBeat·2mo ago
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 2.1% - What's Next?
Prelude Therapeutics (NASDAQ:PRLD) Trading 2.1% Higher - Time to Buy...
MarketBeat·2mo ago
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus
GS stands out as Zacks showcases how its stock picks like MU and PRLD delivered strong gains despite a shaky market.
Zacks·3mo ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...
Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.26) earnings per share for the quarter, topping the consensus...
MarketBeat·4mo ago
Prelude Therapeutics Inc Q3 Loss Decreases, Beats Estimates
(RTTNews) - Prelude Therapeutics Inc (PRLD) revealed Loss for third quarter that decreased from the same period last year and beat the Street estimates...